Oncology Drug Development at Seattle Genetics
Abstract: Dr. Jonathan Drachman’s presentation will focus on two topics. First, the design and utility of antibody-drug conjugates will be reviewed using the clinically validated auristatin payload. Several potential technological advancements in the next generation of ADCs will be discussed. Second, two molecules will be presented that rely on modification of fucosylation as a potential therapeutic strategy in cancer patients. Bio:
Jonathan received his B.A. and M.D from Harvard University and then came to UW for his residency in Internal Medicine and his fellowship in Medical Oncology. After joining Seattle Genetics in 2004, Jonathan has filled many roles, and was most recently named Chief Medical Officer and Executive Vice President, Research and Development in October 2013 to lead the company’s research and development teams. Under his leadership, these teams are united to seamlessly move our scientific research into clinical development. His desire to provide the best possible treatment options for people with cancer drives their innovation. In addition to his work at Seattle Genetics, he has also held the positions of Associate Professor in the Hematology Division, Department of Medicine at the University of Washington and Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. He also serves on the Board of Directors at Calithera Biosciences. Molecular Engineering and Sciences Seminar Series This weekly seminar brings together students, faculty and invited guests from various disciplines across campus to explore current trends in molecular engineering and nanotechnology. It is a forum for active interdisciplinary discussions. These talks are open to the public and attract a diverse audience of students and faculty. |